Notification That Quarterly Report Will Be Submitted Late (nt 10-q)
May 16 2022 - 12:35PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
12b-25
NOTIFICATION
OF LATE FILING
(Check
One): |
|
☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q
☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR |
|
|
|
|
For Period Ended:
March 31, 2022 |
|
|
|
|
☐ Transition
Report on Form 10-K |
|
|
|
|
☐ Transition
Report on Form 20-F |
|
|
|
|
☐ Transition
Report on Form 11-K |
|
|
|
|
☐ Transition
Report on Form 10-Q |
|
|
|
|
For the Transition Period Ended:
|
|
Nothing
in this form shall be construed to imply that the Commission has verified any information contained herein.
|
If
the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:
PART
I — REGISTRANT INFORMATION
HEYU
BIOLOGICAL TECHNOLOGY CORPORATION
Full
Name of Registrant.
Former
Name if Applicable
Room
1901, Baotuo Building, 617 Sishui Street, Huli District
Address
of Principal Executive Office (Street and Number)
Xiamen
City, Fujian Province, China 361000
City,
State and Zip Code
PART
II — RULES 12b-25(b) AND (c)
If
the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b),
the following should be completed. (Check box if appropriate)
☒ |
|
(a) |
|
The
reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense; |
|
|
|
☒ |
|
(b) |
|
The
subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-CEN or Form N-CSR, or portion
thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report
or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the
fifth calendar day following the prescribed due date; and |
|
|
|
☐ |
|
(c) |
|
The
accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable. |
PART
III — NARRATIVE
State
below in reasonable detail the reasons why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR, or the transition report or portion thereof,
could not be filed within the prescribed time period.
HEYU
BIOLOGICAL TECHNOLOGY CORPORATION (the “Company”) is unable, without unreasonable effort or expense, to file its Quarterly
Report on Form 10-Q for the period ended March 31, 2022 (the “10-Q”) by the May 16,
2022 filing due date applicable to smaller reporting companies due to a delay experienced by the Company in completing its financial
statements and other disclosures in the Quarterly Report. As a result, the Company is still in the process of compiling required information
to complete the Quarterly Report. The Company anticipates that it will file the Quarterly Report no later than the fifth calendar day
following the prescribed filing date.
PART
IV — OTHER INFORMATION
(1) |
Name
and telephone number of person to contact in regard to this notification |
|
|
|
|
|
|
|
Bo
Lyu |
|
(86) |
|
158
5924 0902 |
|
(Name) |
|
(Area Code) |
|
(Telephone
Number) |
|
|
(2) |
Have
all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment
Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s)
been filed? If answer is no, identify report(s). Yes ☐ No ☒ |
|
|
|
Quarterly
Report on Form 10-Q for the period ended March 31, 2021
Quarterly
Report on Form 10-Q for the period ended June 30, 2021
Quarterly
Report on Form 10-Q for the period ended September 30, 2021
|
(3) |
Is
it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be
reflected by the earnings statements to be included in the subject report or portion thereof? |
|
|
|
Yes ☐ No ☒
If
so, attach an explanation of the anticipated change, both narrative and quantitative, and, if appropriate, state the reasons why a reasonable
estimate of the results cannot be made. |
HEYU
BIOLOGICAL TECHNOLOGY CORPORATION
(Name
of Registrant as Specified in Charter)
has
caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.
Date:
May 16, 2022 |
By: |
/s/ Bo
Lyu |
|
|
Bo
Lyu |
|
|
Chief
Financial Officer |
4
Heyu Biological Technology (PK) (USOTC:HYBT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Heyu Biological Technology (PK) (USOTC:HYBT)
Historical Stock Chart
From Apr 2023 to Apr 2024